Outlook 2021 – Washington, D.C. Updates and Insights on Life Sciences and Health Care

As a new administration enters the White House, businesses and investors are preparing for potential regulatory and compliance changes. Click here to view our discussion of the most noteworthy developments and issues emanating from DC and their potential impact on life sciences and health care companies in 2021. 

Read the transcript.

Part 1: Focus on FDA
Topics of discussion will include:

• FDA leadership changes, policy priorities and related legislation
• Digital Health: Real World Evidence, Artificial Intelligence and Machine-Based Learning
• Anticipated shifts in FDA enforcement priorities

Part 2: Focus on HHS
Topics of discussion will include:

• Changes in HHS/CMS/OIG priorities, including The Affordable Care Act
• Most Favored Nation rule and other drug pricing prospects
• Congressional Review Act possibilities
• Provider Relief Fund auditing activity

For more resources and insights related to the new administration, please visit our online hub, Capital Insights.